A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment ...
The combination therapy of bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) was both tolerable and produced virologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback